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Background: Alzheimer’s disease (AD) is the most common neurodegenerative disease characterized by neuronal
loss due to amyloid beta aggregations, neurofibrillary tangles, and prominent neuroinflammation. Recently,
interference with neuroinflammation as a new therapeutic approach for AD treatment gained great interest.
Microglia cells, one of the major contributors in neuroinflammation, are activated in response to misfolded proteins
such as amyloid β and cell debris leading to a sustained release of pro-inflammatory mediators. Especially,
complement factor C5a and its receptor have been found to be up-regulated in microglia in the immediate
surroundings of cerebral amyloid plaques and blocking of C5aR resulted in a reduction of pathological markers in a
model of AD. Here, we investigate the effect of active vaccination against the complement factor C5a to interfere
with neuroinflammation and neuropathologic alterations in a mouse model of AD.
Methods: Short antigenic peptides AFF1 and AFF2, which mimic a C-terminal epitope of C5a, were selected and
formulated to vaccines. These vaccines are able to induce a highly specific antibody response to the target protein C5a.
Tg2576 mice, a common model of AD, were immunized with these two C5a-peptide vaccines and the induced
immune response toward C5a was analyzed by ELISA and Western blot analysis. The influence on memory retention
was assessed by a contextual fear conditioning test. Microglia activation and amyloid plaque deposition in the brain
was visualized by immunohistochemistry.
Results: Both C5a-targeting vaccines were highly immunogenic and induced sustained antibody titers against C5a.
Tg2576 mice vaccinated at early stages of the disease showed significantly improved contextual memory accompanied
by the reduction of microglia activation in the hippocampus and cerebral amyloid plaque load compared to control
mice. Late-stage immunization also showed a decrease in the number of activated microglia, and improved memory
function, however, had no influence on the amyloid β load.
Conclusion: C5a-peptide vaccines represent a safe and well-tolerated immunotherapy, which is able to induce a
strong and specific immune response against the pro-inflammatory molecule C5a. In a mouse model of AD,
C5a-peptide vaccines reduce microglia activation and thus neuroinflammation, which is supposed to lead to
reduced neuronal dysfunction and AD symptomatic decline.* Correspondence: christine.landlinger@affiris.com; guenther.staffler@affiris.com
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Alzheimer’s disease (AD) is the most common cause of de-
mentia in the elderly characterized by memory decline and
cognitive dysfunction. Approximately 36 million individ-
uals are currently affected worldwide (WHO 2014). The
main neuropathological hallmarks in AD are extracellular
amyloid β plaques (reviewed in [1]), intracellular neurofib-
rillary tangles (reviewed in [2]), prominent inflammatory
processes (reviewed in [3]), and as a consequence neuron
loss. Originally, the deposition of amyloid β peptides was
considered to be the most crucial step that ultimately leads
to AD dementia described as amyloid cascade hypothesis
[4]. Several therapeutics that targeted amyloid β aggrega-
tion were tested in clinical trials, however, none of them
showed consistent improvements in AD patients (reviewed
in [5, 6]). Although amyloid aggregation is still considered
to be a driving factor in the onset of AD, it is known that
amyloid depositions can occur among the elderly also
without cognitive impairment [7, 8]. In addition, it was
shown in transgenic mouse models that Aβ alone is not
sufficient for cellular and cognitive loss [9].
Besides amyloid β aggregation, a strong activation of
inflammatory processes was observed in the brains of
AD-affected individuals [10–12]. Reactive microglia cells
were found throughout the cortex and hippocampus of
patients with AD and were particularly concentrated in
the areas of plaque formation [13, 14]. The interference
with neuroinflammation has therefore gained consider-
able attention as a potential therapeutic approach in re-
cent years [3, 15].
Inflammatory processes in AD are primarily triggered
by the up-regulation of the complement system in re-
sponse to misfolded and aggregated proteins or mislocal-
ized nucleic acids and reactive microglia [10, 16, 17].
Prolonged chronic neuroinflammation is thought to
reinforce neuronal cell dysfunction and cell death [18, 19].
Notably, the pro-inflammatory complement factor C5a
and its receptor have been found to be up-regulated in
microglia in the immediate surroundings of cerebral amyl-
oid plaques in different mouse models of AD [20]. It was
shown that the blockage of C5aR by the antagonist
PMX205 lead to a therapeutic benefit in a rat model of
neurodegeneration [21]. This inhibitor was also tested in
Tg2576 and 3xTg mice, two different mouse models of
AD, and showed improved memory skills and reduced
amyloid plaque formation [22]. Furthermore, it was re-
ported that C5-deficient DAB/2 mice, which carry the hu-
man APP transgene, had significantly lower Aβ levels
compared to C5-sufficient C57BL/6 mice with the identi-
cal transgene [23].
In this study, we investigate the therapeutic effect of
the interference with neuroinflammation by an active
vaccination directed against the complement factor C5a
in a mouse model of AD.For this propose, two antigenic peptides, which are
able to induce a humoral immune response against a
C-terminal epitope of the murine C5a molecule, were
selected and subsequently tested in wild-type (wt) and
Tg2576 mice. Both peptide vaccines were able to specif-
ically target C5a and found to ameliorate memory defi-
cits and neuropathology in AD-like disease.
Methods
Animals
Both sexes of Tg2576 mice on a 129S6 genetic back-
ground were used (Taconic, Denmark). Tg2576 mice
carry a transgene coding for the 695-amino acid isoform
of the human AD amyloid precursor protein (APP) and
the Swedish mutation (KM670/671NL) [24]. The mice
were bred by the provider by backcrossing hemizygous
male mice with 129S6/SvEvTac female mice. It is re-
ported that memory deficits in this model start at an age
of 6 months and at 9–12 months amyloid plaques in the
cortex and hippocampus become apparent similar to
Tg2576 mice on a C57BL/6 × SJL genetic background
which is a more commonly used strain in the context of
AD-like pathology. Mice on 129S6 background, however,
are supposed to provide more genetic homogeneity and
thus represent a reasonable and validated strain of
Tg2576 mice [25]. 129S6 wt mice were used as a control
(Taconic, Denmark). Mice were housed at the University
of Vienna (Himberg, Austria) and kept under a 12-h
light/dark cycle. Food and water was offered ad libitum.
All animal experiments were performed in accord-
ance with the guidelines for care and use of labora-
tory animals of the Austrian Animal Experiments
Act. The protocol was ethical approved and issued by
the Lower Austrian Provincial government (permit
number: LF1-TVG-22/0102011).
Peptide vaccine preparation and application
The proprietary AFFITOME® technology [26] was used to
develop short immunogenic peptides (AFFITOPE®s),
which mimic a C-terminal epitope of murine C5a. This
technology enables the design of peptides which induce
an antibody response that discriminates between the two
forms of C5a, C5a ARG and the metabolized C5a
desARG. The peptides (AFFITOPE®s) AFF1 and AFF2
were synthesized by FMOC solid phase peptide synthesis
and HPLC-purified (EMC microcollections GmbH,
Germany). These peptides contain an additional N-
terminal cysteine residue and were activated with the
cross linker N-[g-Maleimidobutyryloxy]succinimide ester
(GMBS, Pierce) according to manufacturer’s protocol and
covalently linked to the carrier Keyhole Limpet
Hemocyanin protein (KLH, Biosyn GmbH). The KLH-
conjugated peptides were dissolved in 1× PBS (PAA) and
absorbed to 0.2 % Alhydrogel® (Brenntag Biosector,
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tides were used for one dose of injection, which was ap-
plied subcutaneously in 200 μl. KLH vaccines without the
peptide moiety were used as a control vaccine.
Immunization scheme
Non-AD 129S6 mice (wt mice) were immunized with
AFF1- (n = 12) and AFF2- (n = 12) containing vaccines
as well as vehicle control (n = 12) at the age of 11 months
3 times in a biweekly interval followed by two further
immunizations in monthly intervals.
C5a-peptide vaccination in Tg2576 mice was per-
formed in two studies starting at two different time
points. In the first study, which was timely staggered
into two parts, Tg2576 mice received either C5a-peptide
vaccine AFF1 (n = 23) or AFF2 (n = 23) at the age of
8 months. All animals were immunized 4 times in a bi-
weekly interval followed by three injections once a
month until the age of 13 months. In the second study,
the prime immunization of Tg2576 mice was performed
at the age of 11 months using only AFF1-formulated
vaccine (n = 9). These animals were immunized 4 times
in a biweekly interval followed by the last immunization a
month later. Control treated animals for study 1 (n = 14)
and study 2 (n = 9) were injected with the control vaccine
at the same time intervals as the study groups.
ELISA
To determine the levels of C5a-AFFITOPE® vaccine-in-
duced antibodies, plasma and CSF samples were col-
lected and analyzed by ELISA. Briefly, 1 μM of the
antigenic peptides AFF1, AFF2, or an irrelevant control
peptide all coupled to BSA were coated in 0.1 M
NaHCO3 (pH 9.2–9.4) to a 96-well Nunc-MaxiSorp
plate. In order to test the reactivity against the target
protein, 0.5 μg/ml of the recombinant murine C5a
ARG and C5a desARG (Hycult Biotech) were coated in
1× PBS. Free binding sites were blocked by the incuba-
tion with blocking buffer (1× PBS, 1 % BSA) for 1 h at
37 °C. Plasma (1:100) and CSF (1:10), respectively, were
added, serially diluted 1:2, and incubated for 1 h at 37 °C.
For the detection, biotinylated anti-mu IgG (H + L)
(Southern Biotech.; 1:2000) in 1× PBS/0.1 % BSA/0.1 %
Tween 20 was applied and incubated for 1 h at 37 °C. As a
next step, horseradish peroxidase coupled to streptavidin
(Roche) was added (30 min, 37 °C) followed by the
addition of the substrate 2,2′-Azinobis [3-ethylbenzothiaz-
oline-6-sulfonic acid]-diammonium salt (ABTS) (Bio-
Chemica, AppliChem) (30 min, RT). The optical density
(OD) at 405 nm was measured with a microwell plate
reader (Sunrise, Tecan, Switzerland) and the titers were
defined as the dilution factor referring to 50 % of the max-
imal optical density (ODmax/2). The mean titers ± SEM of
all animals per group are presented.Western blot analysis
Two-hundred nanograms of recombinant mouse C5a
ARG and C5a desARG (Hycult Biotech) were loaded on
a Bio Rad 4–20 % Criterion™ TGX™ gel under non-
reducing conditions. For the detection, immune plasma
(1:50) of AFF1, AFF2, or control immunized Tg2576
mice as well as plasma obtained from untreated wt mice
were used. Rabbit anti-mouse C5a antibody (Abbiotech,
1:200) was used as a control antibody. As a secondary
antibody, a goat anti-mouse HRP IgG (1:20.000) for the
plasma samples and a rabbit anti-goat HRP IgG
(1:20.000) for the control antibody were applied. The
Precision Plus Protein™ Dual Color Standards (Bio-Rad)
was used as a marker.
C5a sandwich ELISA
Changes in the C5a levels in the plasma of individual
Tg2576 mice before (at the age of 8 months) and after
the last immunization (at the age of 15 months) with
AFF1-, AFF2-, and vehicle-containing vaccines was de-
termined by a C5a sandwich ELISA. Briefly, 96-well
Nunc-MaxiSorp plates were coated with the monoclo-
nal rat anti-mouse C5a antibody (R&D, MAB21501).
Plates were blocked with 1× PBS/1 % BSA. Subsequently,
plasma obtained 1 day before the first immunization and
8–9 weeks after the last immunization were applied at a
starting dilution of 1:10 and serially diluted 1:2 in 1× PBS/
0.1 % BSA/0.1 % Tween 20 and incubated for 1 h at 37 °C.
For the detection of bound C5a, the biotinylated poly-
clonal goat anti-mouse complement component C5a anti-
body (R&D, BAF2150) was applied for 1 h at 37 °C.
Horseradish peroxidase coupled to streptavidin (Roche)
was added (30 min, 37 °C) followed by the addition of the
substrate ABTS (BioChemica, AppliChem) (30 min, RT).
The OD at 405 nm was determined by a microwell plate
reader (Sunrise, Tecan, Switzerland). The relative changes
in OD values at a dilution of 1:40 of plasma samples ob-
tained before (=100 %) and after the last immunization of
each individual mouse were evaluated. Plasma obtained
from untreated wt mice was used as a control. The group
means ± SEM of n animals are presented.
Contextual memory test
Contextual learning and memory of C5a-peptide and
control-immunized Tg2576, as well as 129S6 wt mice,
were determined by a contextual fear conditioning test
at the age of 15 months. A contextual fear conditioning
apparatus Ugo Basile 1-cage fear conditioning set-up
(UGO BASILE S.r.l. Biological Research Apparatus Via
Guido Borghi 43; I–21025 Comerio, Varese; Italy) was
used. Fear conditioning training was performed 1 day
before the test. Each mouse was placed in the condition-
ing chamber and exposed to a program allowing the
mouse to habituate for 2 min to the chamber, followed
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30-s rest. The movement of the mouse was monitored
by a camera (Firewire camera Fire-I BBW 1.3 (Uni-
brain)) and analyzed by the computerized tracking soft-
ware ANY-maze (ANY-maze Video Tracking System
4.73–4.91, Stoelting). To assess contextual learning and
memory, 24 h after the initial training, the mouse was
again placed in the conditioning chamber and the ANY-
maze video tracking software was started. This time, the
animal received no electric shocks. Each mouse was
monitored in the chamber for 5 min for immobile epi-
sodes (i.e., time freezing) representing their ability to re-
call the foot shocks they received the previous day.
Modified SHIRPA test
129S6 wt mice were immunized with AFF1-, AFF2-, or
vehicle-containing vaccines starting at the age of
11 months and at the age of 15 months, comprehen-
sive analyses of general health, muscle function, and
sensory function were performed by a modified
SHIRPA test as previously described at the European
Mouse Phenotyping Resource Standardized Screens
(EMPReSS) database (http://empress.har.mrc.ac.uk/).
Briefly, eye closure (score 0 = no, score 1 = yes/normal),
missing whiskers (score 0 = no/normal, score 1 = yes),
tail curl (score 0 = abnormal, score 1 = normal), re-
spiratory function (score 0 = gasping/arrhythmic, score
1 = normal), and body weight were evaluated for gen-
eral health parameters. For the evaluation of the sen-
sory abilities, visual forepaw reach (score 0 = no, score
1 = weak, score 2 = clear placing reaction/normal),
auditory startle (score 0 = no, score 1 = present/nor-
mal), and ear and whisker twitch (score 0 = absent,
score 1 = present/normal) were assessed. The muscle
functions were evaluated based on pelvic elevation (score
0 = low, score 1 = normal), truck curl (score 0 = absent,
score 1 = present/normal), righting reflex (score 0 = absent/
impaired, score 1 = present/normal), clasping (score 0 = no,
score 1 = 1 paw, score 2 = 2 paws), forelimb grip (score
0 = no, score 1 = weak, score 2 = normal), and grasping
reflex (score 0 = no/all 4 paws impaired, score 1 = fore
and hind limbs impaired, score 2 = all 4 paws normal).
Immunohistochemistry and image analysis
The mouse brain was isolated and without perfusion,
the left hemi-brain was fixed o/n in 4 % paraformalde-
hyde (PFA, Merck) at 4 °C. The tissue was embedded in
paraffin, and coronal sections (7 μm) containing the
frontal, middle, and distal hippocampal region (bregma
distance −1.60, −2.10, and −2.60 mm) were used for im-
munohistochemical staining. After rehydration and
treatment with antigen retrieval pH = 9.0 (Dako), the tis-
sues were blocked with 4 % normal goat or rabbit serum,
respectively (Sigma). Serial sections were incubated withthe corresponding primary antibody or control IgG. Aβ
deposits were detected by an in-house generated mouse
3A5 monoclonal antibody (mAB) that specifically binds
to the N-terminal part of Aβ [27]. Activated CD45high
microglia cells were visualized by the goat anti-mouse
CD45 antibody (AF114) obtained from R&D systems.
Fluorescent anti-mouse IgG (H + L) and Fluorescent
anti-goat IgG (H + L) (Vector Laboratories) were used
for the detection of 3A5 and CD45 antibody, respect-
ively. The cover slides were mounted with Vectashield®
Hard Set™ Mounting Medium with 4′,6-diamidino-2-
phenylindole (DAPI) (Vector Laboratories), dried for
2 days in the dark. Slides were then scanned by the
Mirax Scan 150 automated whole slide scanner (Karl
Zeiss AG). The relative amyloid plaque area (3A5 stain-
ing) within the total tissue area of coronal cross sections
of the brain including the cortex, hippocampus, and the
brain stem was analyzed by a semi-automated area rec-
ognition program (eDefiniens Architect XD; www.defi-
niens.com). CD45high cells in the hippocampal region
were counted manually. Immunostaining and analysis of
each marker was performed from 6–12 sections of each
individual mouse brain derived from 3 defined bregma
distances all including the hippocampal region. The
mean value of all sections per mouse was calculated and
the means per group ± SEM of n animals are presented.
Statistical analysis
All values were evaluated for homoscedasticity and nor-
mality assumption using both Kruskal-Wallis and
Shapiro-Wilk normality tests. To determine statistical
significance of more than two groups, values were com-
pared using one-way ANOVA followed by the Tukey’s
multiple comparison tests (parametric test) or one-way
ANOVA with the Dunn’s test (non-parametric test). For
the comparison of two groups, the unpaired two-tailed
Student’s t-test was used, followed by the Mann-
Whitney correction for non-parametric data as indicated
in the respective figure legend.
The p values ≤0.05 were considered significant and are
expressed as *p < 0.05 and **p < 0.01.
Results
Immunogenicity and safety of anti-C5a-peptide vaccines
in wt mice
Peptides (AFFITOPE®s) mimicking the C-terminal neo-
epitope of murine C5a were designed, formulated, and
tested in 129S6 wt mice for their immunogenicity and
ability to induce antibodies against the endogenous tar-
get protein C5a (Fig. 1). C5a is present in two different
forms, the highly active C5a ARG which becomes rap-
idly metabolized by a carboxypeptidase to the less active
though more stable C5a molecule without the C-
terminal arginine, C5a desARG. As the relevance of the
Fig. 1 C5a-peptide vaccines are immunogenic and induce a target-specific antibody response in wt mice. 129S6 wt mice were immunized 4 times
with AFF1- (n = 12) and AFF2- (n = 12) containing vaccines starting at the age of 11 months. Control mice (n = 12) were immunized 4 times with a
KLH-only vaccine. Plasma samples obtained after the last immunization were analyzed by ELISA. a The mean IgG antibody titers (ODmax/2) against the
injected peptides AFF1 and AFF2 and against an irrelevant peptide. b The mean titers against the target protein C5a present in its two forms C5a
desARG and C5a ARG. Bars represent the group means ± SEM of n animals
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ease is still unknown, different C5a-targeting peptides
(AFFITOPE®s), AFF1 and AFF2, have been selected for
in vivo testing. Both AFF1- and AFF2-containing vac-
cines elicited similarly high titers of approximately 1/
50.000 against their antigenic peptide moiety (Fig. 1a).
No cross-reactivity against an unrelated irrelevant pep-
tide was observed (Fig. 1a). However, their reactivity
against the different forms of the target protein differed.
AFF1-containing vaccine mounted higher antibody titers
against C5a desARG, whereas AFF2-containing vaccine
primarily induced a strong immune response against the
more active molecule, C5a ARG (Fig. 1b). As expected,
control immunized mice did not show any immune re-
sponse against C5a ARG and C5a desARG (Fig. 1b).
Before testing the C5a-peptide vaccines for their efficacy
in a mouse model of AD, we investigated whether these
vaccines had any effect on the contextual learning and
memory in 129S6 wt mice by using the contextual fear
conditioning test. After four immunizations, no differences
between the control and the C5a-AFFITOPE® immunized
mice were observed all showing around 60 % time freezing
within a 2-min period of analysis (Fig. 2a). Furthermore,
potential side effects of the vaccines were evaluated by a
modified SHIRPA test including general health, muscle,
and sensory functions. C5a-peptide and vehicle-immunized
129S6 wt mice were all healthy (Fig. 2b), had comparable
body weight (Fig. 2c), and no abnormalities in sensory and
motor functions were observed (Fig. 2d, e). In addition, dif-
ferent safety parameters were elucidated by in silico ana-
lyses. The absence of target-specific T cell response and
cross-reactivity of vaccine-induced antibodies to other en-
dogenous proteins are a prerequisite for an immunother-
apy against self-proteins in order to avoid the risk of
autoimmunity. In silico analysis by online available T cell
epitope prediction algorithms (e.g., http://www.syfpeithi.deor http://www.iedb.org/counts.php) did not predict any
relevant T cell epitope for the peptides AFF1 and AFF2.
Potential cross-reactivity of the AFF1- and AFF2-induced
antibodies to other proteins was evaluated by BLAST
searches against the murine proteome. AFF1 did not show
any relevant homology to other murine proteins. For
AFF2, a homology of 6 amino acids to FYN binding pro-
tein was found, however, based on its intracellular location,
it is not anticipated to be accessible for antibody binding.
Immunogenicity in Tg2576 mice
Human APP transgenic Tg2576 mice on a 129S6 gen-
etic background were used as a model of AD-like dis-
ease. In a first study, starting at the age of 8 months,
Tg2576 mice were either immunized with AFF1- or
AFF2-formulated anti-C5a vaccines. Two weeks after
the second immunization (W4), titers against the im-
munizing peptides AFF1 and AFF2 approached ap-
proximately 1/20.000 and 1/45.000, respectively, and
remained at this level until week 28 (W28) correspond-
ing to 15 months of age (Fig. 3a). Compared to the re-
sults obtained from immunized wt mice, AFF2-
containing vaccines induced similar high titers against
the antigenic peptide AFF2, whereas AFF1-containing
vaccines elicited a clearly lower titer against the peptide
moiety (Figs. 1a and 3a). ELISA for the proteins C5a
desARG and C5a ARG revealed that AFF1-containing
vaccine mounted higher antibody titers against C5a
desARG whereas AFF2-containing vaccine showed a
much higher immune response against C5a ARG
(Fig. 3b), similar to those results obtained from AFF1
and AFF2 immunized wt mice (Fig. 1b). As expected,
control immunized mice did not show any immune re-
sponse against the C5a proteins (Fig. 3b). Western blot
analyses using recombinant C5a ARG and C5a desARG
confirmed this reactivity pattern of AFF1- and AFF2-
Fig. 2 Wt mice treated with C5a-peptide vaccines show normal contextual learning and memory skills and are healthy with normal motor and sensor
function. 129S6 wt mice immunized with AFF1- (n = 12) and AFF2- (n = 12) containing vaccines were compared to vehicle immunized mice (n = 12)
for a contextual memory function using a contextual fear conditioning test, b general health status, c body weight, d sensory functions, and e motor
functions using the modified SHIRPA test. All tests were performed at the age of 15 months. Bars represent the group means ± SEM of n animals
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showed a better recognition for C5a desARG, whereas
AFF2-induced immune plasma revealed a stronger
band for C5a ARG. Control immunized mice as well as
plasma obtained from untreated wt littermates at the
age of 15 months did not show any signal toward both
forms of C5a (Fig. 3c).
In order to assess whether AFF1- and AFF2-induced
antibodies reach their target in the brain, cerebrospinal
fluid (CSF) was obtained and analyzed for the presence of
AFFITOPE®-specific antibodies by ELISA. Antibodies
could be detected in the CSF ranging from 0.2 to 0.4 % of
their corresponding titers in plasma (Fig. 3d).
C5a-peptide vaccines deplete C5a from the circulation
The plasma concentration of C5a was used as a surrogate
for antibody binding efficacy to C5a of vaccine-induced
antibodies. The changes of the total C5a levels in the
plasma obtained before (refers to 100 %) and after the last
immunization of AFF1, AFF2, and control immunized
Tg2576 mice were assessed. The levels of C5a were signifi-
cantly reduced to 68 and 72 % in AFF1- and AFF2-treated
mice, respectively, whereas control immunized mice
showed an increase of C5a up to 124 % (Fig. 4), indicating
an in vivo target engagement of AFFITOPE®-inducedantibodies. As an additional control, plasma from un-
treated wt mice was analyzed showing a constant level of
C5a in the plasma of 8- vs. 15-month-old mice (Fig. 4).
Early stage immunization improves contextual memory
and reduces the number of activated microglia and
amyloid plaque load in Tg2576 mice
In a first set of experiments, anti-C5a immunization of
Tg2576 mice by AFF1- and AFF2-containing vaccines was
started at the age of 8 months, where first memory deficits
are reported to become apparent in this model, but amyl-
oid plaques in the brain are not yet present. A contextual
fear conditioning test was performed at the age of
15 months in order to investigate the impact of C5a-
targeting vaccines on the progression of AD-like cognitive
decline. The time freezing was used to measure mice’s
ability to recall the shocks they received on the previous
day. Both AFF1- and AFF2-vaccinated mice showed sig-
nificantly increased memory retention with 32 and 27 %
time freezing, respectively, whereas control-treated mice
spent only 10 % time freezing indicating an almost
complete loss of contextual learning and memory (Fig. 5).
However, vaccination was not able to restore the context-
ual learning and memory conditions which were found in






















































































Fig. 3 C5a-peptide vaccines induce target-specific antibody response in Tg2576 mice. a Tg2576 mice were immunized with AFF1- (n = 12) and
AFF2- (n = 13) containing vaccines 4 times in biweekly intervals (week 0, 2, 4, and 6) followed by 3 boosts in a monthly interval (week 11, 15, and
19). The immunizations are indicated by an asterisk. Plasma samples were collected at the indicated time points (week 2–28). All samples were
analyzed by ELISA and the mean IgG antibody titers (ODmax/2) against the injected peptide AFF1 and AFF2 are presented. b The titers against
both forms of the target protein, C5a desARG and C5a ARG, were analyzed in the plasma obtained after the last immunization in W28. Also
control immunized mice (n = 11) were tested against C5a proteins (c). Western blot analyses where recombinant C5a ARG and C5a desARG were
loaded and detected by AFF1 (second panel), AFF2 induced immune plasma (third panel), as well as plasma obtained from control immunized
mice (fourth panel), and untreated wt mice (fifth panel) as a negative control. Rabbit anti-mouse C5a antibody was used as a positive control
(first panel). The Precision Plus Protein™ Dual Color Standards (Bio-Rad) was used as a marker. d CSF was obtained from five randomly selected
AFF1 and AFF2 immunized mice and tested for AFFITOPE®-specific antibodies in week 28. All data points represent the group means ± SEM of
n animals
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study. To evaluate that the memory improvements in
AFF1- and AFF2-vaccinated Tg2576 mice can be attrib-
uted to the neutralization of excessive C5a which was pro-
voked by the APP transgene, an independent control
experiment was performed. Wt mice were immunized 4
times with AFF1 and AFF2 vaccines and tested for mem-
ory retention by a contextual fear conditioning test. No
differences between the control and the C5a-AFFITOPE®-
immunized mice were found as already shown in Fig. 2a.
In order to investigate the impact of anti-C5a vac-
cination on microgliosis in the hippocampus, immu-
nohistochemical analysis of CD45high cells in the brain
of AFF1-, AFF2-, and control-treated Tg2576 mice at
the age of 15 months was performed (Fig 6a). Com-
pared to control, both AFF1- and AFF2-formulated
vaccines significantly reduced the number of CD45-
positive (CD45high) microglia in the hippocampus
(Fig. 6b).We further analyzed whether anti-C5a vaccination also
had an influence on the cerebral Aβ pathology, a major
hallmark of AD progression. The in-house generated Aβ-
specific mAB 3A5 [27] was used to detect Aβ depositions
in the brain of 15-month-old mice treated with AFF1,
AFF2, or the control vaccine (Fig. 6c). Both, AFF1- and
AFF2-treated mice, revealed a statistically significant re-
duction of cerebral amyloid burden exhibiting 0.39 % in
AFF1 (p < 0.01) and 0.42 % (p < 0.05) in AFF2 amyloid
plaque area of the total coronal brain section, compared
to 0.55 % in control immunized mice (Fig. 6d).
Late-stage vaccination improves memory function and
reduces the number of activated microglia but has no
influence on amyloid burden in the brain
In order to determine if the beneficial effects of our anti-
C5a vaccines which were observed upon early stage treat-
ment could also be seen in a more progressed stage of
Alzheimer-like disease, AFFITOPE® immunization was
Fig. 5 Contextual memory is significantly improved following
C5a-peptide vaccination. A CFC test was performed with AFF1 (n= 23),
AFF2 (n= 23), and control (n= 14) immunized Tg2576 mice, as well as
wt littermates (n= 12), all at the age of 15 months. Mice were exposed
to electric foot shocks and the memory to recall these shocks was
assessed by the percent time freezing in a 2-min interval. Bars represent
the group means ± SEM of n animals. The p value was determined using
one-way ANOVA test followed by a Dunn’s multiple comparison Test
(non-parametric test). The p values are expressed as *p< 0.05
and **p< 0.01
Fig. 4 Depletion of C5a from the circulation through C5a-peptide
vaccination. The changes of C5a concentration in the plasma of Tg2576
mice before (at the age of 8 months) and after the treatment (at the age
of 15 months) with AFF1- (n= 12), AFF2- (n= 13), or vehicle- (n= 11)
containing vaccines were determined by sandwich ELISA. The level of
C5a in the plasma obtained before the immunization start at the age of
8 months refers to 100 %. The C5a level in the plasma of untreated wt
mice (n= 6) at the age of 8 months vs. 15 months is also shown. Bars
represent the group means ± SEM of n animals. The one-way ANOVA
test followed by a Tukey’s multiple comparison Test (parametric test) was
applied to determine the p values (*p< 0.05 and **p< 0.01)
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and cerebral amyloid depositions are already clearly pro-
nounced. Mice were immunized with AFF1-containing
vaccines 4 times in a biweekly interval followed by the final
immunization 1 month later. A contextual fear condition-
ing test was performed at the age of 15 months in order to
assess the influence of the anti-C5a vaccination on memory
impairment. Compared to the control vaccine, AFF1-
vaccinated mice showed a tendency of better contextual
learning and memory skills indicated by 18 % vs. 7 % time
freezing (Fig. 7a, p = 0.182). Untreated wt littermates
showed 51 % time freezing similar to the result obtained in
Fig. 5. Again, wt littermates treated with AFF1 vaccine have
not been included in this study. However, an independently
performed control experiment showed that the memory
retention of control and AFF1-immunized wt mice was
similar (see Fig. 2a).
When evaluating the number of CD45high microglia
cells in the hippocampus, a significant reduction in
AFF1 compared to control-treated Tg2576 mice was
found (Fig. 7b).
In contrast to Tg2576 mice immunized at an early
stage of the disease (Fig. 6d), cerebral amyloid burden
was not reduced upon late-stage treatment with anti-
C5a vaccine (Fig. 7c).
Conclusion
Active vaccination against the pro-inflammatory molecule
C5a represents a novel and well-tolerated therapeuticapproach to interfere with neuroinflammation in a mouse
model of AD. Early- as well as late-stage treatment with
C5a-peptide vaccines reduced microgliosis and improved
cognitive function. Amyloid plaque burden, however, was
only affected in an early onset of vaccination, thus we sup-
pose that C5a-mediated neuroinflammation more than
amyloid β aggregation is a driving factor for memory de-
cline in this model of AD.
Discussion
The present study shows that active immunization with
C5a-peptide vaccines AFF1 and AFF2 elicits antibodies
that effectively bind C5a and reduce the number of acti-
vated microglia in the hippocampus, accompanied by
memory improvements in a mouse model of AD. More-
over, cerebral amyloid plaque load was decreased upon
an early-stage treatment with C5a-peptide vaccines.
An early characteristic of AD is the generation of
amyloid proteins by the increased proteolytic cleavage of
amyloid precursor proteins (APP) which start to accu-
mulate and aggregate especially in the hippocampal and
cortical region of the brain. Neuroinflammation also
plays a critical role in the pathogenesis of AD, although
the mechanisms through which amyloid aggregation and
deposition provoke inflammation are not fully under-
stood. Microglia attraction and activation by amyloid
plaque formation may play a detrimental role (reviewed
in [10, 12]). Microglia can be activated by direct inter-
action with misfolded or aberrant endogenous molecule
patterns via pattern recognition receptors (PRRs) includ-
ing scavenger receptor (SR-AI/II), CD36, RAGE, FC
CD45 
Ctr AFF1 AFF2 wt 
3A5 
Ctr AFF1 AFF2 wt 
A B 
D C 
Fig. 6 At an early stage of disease, C5a-peptide vaccines reduce the number of activated microglia and amyloid plaque load in the brain. a Brain
sections of 15-month-old Tg2576 mice immunized with either AFF1 (n= 23), AFF2 (n= 23), or control (n= 14) vaccines were stained for CD45-positive
microglia cells (green). b The average number of CD45high cells in the hippocampal region of all sections. c Amyloid plaques visualized by the 3A5 mAB
(green) (d). Percentage of amyloid area of the total brain sections all containing the hippocampal region was calculated by the eDefiniens
Software. a, c Cell nuclei were stained with DAPI (blue) and the scale bar refers to 100 μm. b, d Bars represent the group means ± SEM of n animals. The
p value was determined using one-way ANOVA test followed by a Dunn’s multiple comparison Test (non-parametric test) and expressed as
*p< 0.05 and **p< 0.01
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important mechanism of microglia recruitment and acti-
vation is complement activation in response to Aβ de-
position [30, 31] which leads to the formation of the
pro-inflammatory molecule C5a. C5aR was shown to be
up-regulated in microglia in the immediate surroundings
of plaques in the brain of different transgenic mouse
models of AD [20].
Activation of microglia by Aβ and complement is
supposed to promote the excessive release of pro-
inflammatory cytokines [32], chemokines [33, 34], and
further complement components [35, 36], as well as the
release of reactive oxygen and nitrogen species [37, 38],
altogether leading to dysfunction and loss of synapse
signaling [39]. Pro-inflammatory mediators provoke a
number of stress conditions which, in turn, can en-
hance APP production and processing to amyloid pep-
tides (Aβ 1–42) [40–45]. Thus, chronic and self-
sustaining inflammatory interactions between the com-
plement system, activated microglia, stressed neurons,
and Aβ plaques occur, which ultimately lead to neur-
onal cell death and cognitive decline in AD patients.
Our intention was to target the pro-inflammatory com-
plement activation product C5a in order to interfere
with enhanced microglia activation and sustained neu-
roinflammation in AD (Fig. 8).There are several publications that describe a physio-
logical role for the anaphylatoxins C3a and C5a within the
adult murine CNS, specifically an involvement in cell sur-
vival and neurogenesis ([46] and reviewed in [47–49]).
Neuroprotective effects of C3a and C5a have been re-
ported against glutamate-mediated neuronal excitotoxicity
via MAPK-dependent inhibition of caspase-3 [50–52] and
increased glial expression of the glutamate transporter
GLT-1 [53]. In addition, administration of C5a in vivo has
been shown to protect against kainic acid-induced neur-
onal apoptosis [52]. However, activation of complement
and the release of C3a and C5a to an inappropriate extent
has been proposed to promote tissue injury.
In the pathogenesis of AD, the complement factors
C1q [54] and C3 [55] have been reported to promote
phagocytosis and clearance of fibrillar Aβ and thus
hinder pathologic progression in AD. The complement
component C5a, however, is supposed to play a detri-
mental role in neurodegenerative diseases by persist-
ent microglia activation resulting in excessive release
of microglial inflammatory mediators, which enhance
Aβ deposition and neuroinflammation [40, 42, 43]. It
was shown that the blockage of C5aR by the antagonist
PMX205 lead to a therapeutic benefit in different models
of neurodegeneration [21, 22], which strengthens our hy-
pothesis that interference with C5a by vaccination
Fig. 7 Vaccination at a progressed stage of disease improves memory function and reduces microgliosis but had no effect on the amyloid plaque
load in the brain. a Tg2576 mice which were immunized with AFF1- (n = 9) and control (n = 9) vaccines at the age of 11 months, as well as wt
littermates (n = 24) were exposed to a contextual fear conditioning test. b Average number of CD45high cells in the hippocampal region analyzed by
immunohistochemistry. c The percentage of amyloid plaque area of the total brain sections. The bars represent the group means ± SEM of n animals.
The unpaired two-tailed Student’s t-test was used for statistical analysis, whereas in Fig. 7a, a Mann Whitney correction for non-parametric data was
performed. A p value of ≤0.05 was considered to be statistically significant
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and AFF2, when coupled to the carrier protein KLH and
formulated with Alhydrogel®, were able to induce a strong
and prolonged humoral immune response against the tar-
get protein C5a in mice. Upon immunization, a reduction
of total C5a in the plasma was found which indicated an
effective in vivo target engagement. AFF1 and AFF2 were
selected for in vivo studies, because these two peptides
possess different immunogenic features. AFF1-induced
antibodies react against both forms of C5a, the highly ac-
tive C5a ARG but to a higher extent against the metabo-
lized, less active, and more stable C5a desARG (Figs. 1b
and 3b), whereas immune plasma elicited by AFF2 vac-
cines especially showed high titers against C5a ARG
(Figs. 1b and 3b). To date, the distinct function of the twoforms of the anaphylatoxin C5a and their contribution to
chronic inflammatory diseases, such as AD, are not under-
stood. AFF1 compared to AFF2 vaccine was found to be
slightly more efficient in Tg2576 mice in terms of context-
ual memory retention (Fig. 5) raising the possibility that
C5a desARG more than C5a ARG contributes to neuro-
inflammation in AD.
Most of the vaccine-induced antibodies were present in
the circulation, however, a lower proportion (0.2–0.4 %)
can also be detected in the CSF which let us assume that
vaccine-induced anti-C5a antibodies directly reach their
target in the brain. Immunohistochemistry, ELISA, and
Western blot analyses were performed in order to show
local anti-C5a antibody effects, but unfortunately the sensi-
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Fig. 8 Model of C5a-peptide vaccines interference with chronic, self-sustaining inflammatory processes in AD. APP processing to amyloid
peptides (Aβ 1–42) is influenced by an unknown trigger. Aβ peptides start to aggregate in the brain and microglia become activated either
by a direct interaction with misfolded Aβ molecules via pattern recognition receptors (PRR) or by complement activation in the response to
Aβ depositions leading to the formation of the pro-inflammatory molecule C5a. We propose that C5a-AFFITOPE® vaccines interfere with the
pro-inflammatory molecule C5a thereby hindering enhanced microglia activation which leads to excessive release of pro-inflammatory
mediators. These pro-inflammatory mediators provoke stress conditions, which in turn reinforce APP production and processing to amyloid
peptides (Aβ 1–42). We believe that C5a-AFFITOPE® vaccines do have the capacity to interfere with chronic and self-sustaining inflammatory
interactions between activated microglia, stressed neurons, and Aβ plaques which ultimately lead to neuronal cell death and cognitive decline
in AD patients
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fects, the clearance of C5a from the periphery, which we
were able to show in Fig. 4, may play a crucial role in the
treatment of neurodegenerative diseases, since a secondary
systemic inflammatory stimulus is hypothesized to affect
exaggerated response of microglia which possibly contrib-
utes to disease progression (reviewed in [56, 57]).
We found that both early (at the age of 8 months)
and late (at the age of 11 months) onset of anti-C5a
immunotherapy reduced the number of activated
microglia in the hippocampus (Figs. 6b and 7b) and im-
proved contextual learning and memory in 15-month-
old Tg2576 compared to control-treated mice (Figs. 5
and 7a) indicating that neuroinflammation is directly
involved in memory decline and C5a may be a crucial
factor that drives this inflammation. To be sure that
amyloid is the main factor that provokes complement
activation in Tg2576 mice and thus memory decline, an
additional group of wt littermate mice immunized with
anti-C5a vaccines should have been included in the
above presented experiments. Since these data are not
available, we cannot exclude that a secondary inflamma-
tory stimulus may contribute to the outcome or progres-
sion of AD-like disease in these animals. However, the
effect of anti-C5a immunization on non-transgenic mice
was tested in an independently performed control experi-
ment which showed that C5a-AFFITOPE® immunization
did not influence the cognitive behavior (Fig. 2a).
Besides the contextual fear conditioning test, also the
classical Morris water maze test, another hippocampal
dependent complex learning tasks, was performed. Similar
results were obtained (data not shown), although a con-
textual fear conditioning test seems to be more reliable.As analyzed by Owen et al., contextual fear conditioning
detected less variability across genotypes and thus appears
to be more broadly applicable to studies of complex learn-
ing in mice compared to Morris water maze task [58].
Cerebral amyloid plaque load was only reduced in
mice vaccinated at an early and not at a late stage of
Alzheimer-like disease (Figs. 6d and 7c). This observa-
tion indicates that already existing amyloid β plaques
cannot be reduced through anti-C5a vaccination
whereas initial deposition can be alleviated significantly
by anti-C5a interference. Interestingly, Fonseca et al.
found a reduction of amyloid plaque load in Tg2576
mice upon treatment with PMX205, a C5aR inhibitor,
starting at the age of 12 months [22]. The difference
between our study and previously presented data may
be due to the different interference strategies. Specific-
ally, treatment with small molecules, such as PMX205,
may immediately be effective, whereas an active
immunization approach using C5a-peptide vaccines
takes at least 4–6 weeks to mount an appropriate anti-
body response.
The major advantage of an active immunotherapy vs.
the application mAbs or small molecules however is that
prolonged therapeutic effects can be easily achieved by
booster immunizations (Fig. 3a) whereas mAB and small
molecule therapy is linked to frequent treatments and
mostly high costs.
All immunotherapeutic approaches which target self-
proteins have to consider the issue of potential auto-
immunity. Thus, a prerequisite of our peptide vaccines was
to stimulate the humoral immune system and induce spe-
cific and effective antibodies against complement factor
C5a without inducing target-specific T cells and thereby
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threatening consequences. The proprietary AFFITOME®
technology favors the use of short epitope-specific peptides
(<13 aa) which do not bind to MHC class II molecules.
Peptides (AFFITOPE®s) become antigenic only when
coupled to a carrier protein (e.g., KLH) which provides T
helper cell epitopes. Thus, immunization with AFF1 and
AFF2 induces an effective B cell response and concurrently
circumvents target-specific CD4 T cell activation. However,
peptides which exceed 7 amino acids potentially activate
MHC class I-restricted CD8 positive T cells. Analysis by
online available T cell epitope prediction algorithms did
not predict any relevant T cell epitope for the anti-C5a
peptides AFF1 and AFF2. These in silico data were further
confirmed by in vivo immunization experiments where no
abnormalities in terms of mortality, weight loss, sensory
and motor functions, handling behavior, and contextual
memory skills of wt mice treated with the C5a-peptide vac-
cines were observed (Fig. 2a–d). Therefore, C5a-peptide
vaccines represent a safe and well-tolerated immunother-
apy, which is able to elicit a specific and long lasting im-
mune response against C5a (Figs. 1a and 3a) without any
relevant cross-reactivity. Another safety aspect of our vac-
cination approach was to target only C5a and not C5 or
C5b, in order to interfere only with a terminal detrimental
component of the complement system. Potentially protect-
ive complement activation events more upstream import-
ant for the clearance of aggregated proteins and cell debris
will be maintained [54].
We showed that C5a-AFFITOPE® vaccination is able to
target the pro-inflammatory complement activation prod-
uct C5a, thus preventing enhanced microglia activation in
the hippocampus, reducing memory decline and Aβ path-
ology in a model of AD.
Thus, active immunotherapy against complement factor
C5a is a new and effective approach for the treatment of
AD-like disease. Moreover, these promising results suggest
a therapeutic potential of C5a vaccination not only in AD
but also for other indications in which chronic inflamma-
tory processes driven by complement activation may play
a pivotal role.
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